ACR Open Rheumatology (Feb 2021)

Takayasu Arteritis: a Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments

  • Anisha B. Dua,
  • Mohamad A. Kalot,
  • Nedaa M. Husainat,
  • Kevin Byram,
  • Jason M. Springer,
  • Karen E. James,
  • Yih Chang Lin,
  • Marat Turgunbaev,
  • Alexandra Villa‐Forte,
  • Andy Abril,
  • Carol Langford,
  • Mehrdad Maz,
  • Sharon A. Chung,
  • Reem A. Mustafa

DOI
https://doi.org/10.1002/acr2.11186
Journal volume & issue
Vol. 3, no. 2
pp. 80 – 90

Abstract

Read online

Objective Takayasu’s arteritis (TAK) is a granulomatous large‐vessel vasculitis primarily affecting the aorta and its proximal branches. TAK can be a difficult disease to diagnose and manage given the rarity of the disease as well as current limitations in biomarkers, imperfect imaging modalities, and few randomized controlled trials. Methods In developing the American College of Rheumatology/Vasculitis Foundation guideline for the management of TAK, we performed an extensive systematic literature review to guide our recommendations. We included RCTs first. When RCTs were not available, we included observational studies that reported on patient‐important outcomes for the intervention and comparison. When studies with comparative data were not available, we included case series that present patient‐important outcomes for either the intervention or the comparison. Results Three hundred forty‐seven articles were included for full review to answer 27 population, intervention, comparison, and outcome questions related to TAK. Ten studies were evaluated that addressed the use of glucocorticoids (GCs), non‐GC nonbiologic therapies, as well as biologics in treating TAK. A total of 33 studies, including 8 comparative studies, were included to determine the test accuracy of commonly available diagnostic tests for TAK. Conclusion This comprehensive systematic review synthesizes and evaluates the benefits and harms of different treatment options and the accuracy of commonly used tests for the management of TAK.